However, this mechanism seems not fitting well in cisplatin-based bladder cancer chemotherapy as miR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status [9]. This evidence concerns the gene RB1 and urinary bladder carcinoma.